Back to top

uniQure reports preliminary data on first cohort in Phase I/IIa trial of AMT-260

uniQure (QURE) announced initial six-month follow-up data on the first, low dose cohort of six patients in its ongoing Phase I/IIa trial of an inve...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

uniQure N.V. (QURE)